Details for Patent: 12,233,074

« Back to Dashboard

Which drugs does patent 12,233,074 protect, and when does it expire?

Patent 12,233,074 protects NEXTSTELLIS and is included in one NDA.

Summary for Patent: 12,233,074

Title:	Contraceptive methods with improved pearl index
Abstract:	Described are methods of providing contraception in a woman having a BMI≥30.0 kg/m2, comprising: selecting a woman determined to have a BMI≥30.0 kg/m2, and then orally administering to the selected woman a therapeutically effective amount of an estetrol component at a daily dose of from 14 mg to 16 mg, based on the estetrol moiety, and drospirenone at a daily dose of from 2.5 mg to 3.5 mg. Also described are methods of contraception that achieves a Pearl Index of <5 in women having a BMI≥30.0 kg/m2, comprising: selecting a woman determined to have a BMI≥30.0 kg/m2, and then orally administering to the selected woman a therapeutically effective amount of an estetrol component at a daily dose of from 14 mg to 16 mg, based on the estetrol moiety, and drospirenone at a daily dose of from 2.5 mg to 3.5 mg, wherein the method comprises daily administration of the estetrol component and drospirenone on 24 consecutive days followed by a hormone-free period of 4 consecutive days.
Inventor(s):	Jean-Michel Foidart, Maud JOST
Assignee:	Estetra SRL
Application Number:	US18/107,703
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 12,233,074

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Mayne Pharma	NEXTSTELLIS	drospirenone; estetrol	TABLET;ORAL	214154-001	Apr 15, 2021		RX	Yes	Yes			Y			USE BY FEMALES OF REPRODUCTIVE POTENTIAL TO PREVENT PREGNANCY